MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
75.48
-0.28
-0.37%
After Hours: 75.48 0 0.00% 17:25 12/31 EST
OPEN
75.54
PREV CLOSE
75.76
HIGH
76.97
LOW
75.10
VOLUME
538.46K
TURNOVER
--
52 WEEK HIGH
80.99
52 WEEK LOW
26.20
MARKET CAP
5.16B
P/E (TTM)
-17.3020
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE)
TipRanks · 12/30/2025 11:30
J&J failure likely a ‘clearing event’ for Apogee Therapeutics, says BTIG
TipRanks · 12/29/2025 20:45
Weekly Report: what happened at APGE last week (1222-1226)?
Weekly Report · 12/29/2025 09:55
Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares
Reuters · 12/24/2025 01:00
Weekly Report: what happened at APGE last week (1215-1219)?
Weekly Report · 12/22/2025 09:55
Apogee Therapeutics price target lowered to $81 from $82 at BofA
TipRanks · 12/19/2025 14:10
Apogee Therapeutics (APGE) Gets a Buy from Bank of America Securities
TipRanks · 12/19/2025 10:55
Apogee Therapeutics Initiated at Overweight by Stephens & Co.
Dow Jones · 12/17/2025 13:42
More
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.